"A question that probably some of you are thinking of ... which I find to be very interesting. So, supposedly we hit the body with a tremendous, whether it’s ultraviolet or just very powerful light... inside the body ... Sounds interesting, right? ... It sounds interesting to me." President Trump caught a lot of flak last week for -- so the story goes -- urging patients infected with the novel coronavirus SARS-CoV-19 to "drink bleach" in order to "disinfect" themselves from the inside out. Sadly, the President then proceeded to mix his advice with some less-than-coherent musings about "injections" and "cleanings" and "disinfectants" -- and calls to U.S. poison control centers apparently spiked in response to those comments.But that doesn't mean the President was completely in the wrong. In fact, one company thinks he might be on to something.Tiny Englewood, Colorado-based microcap Aytu BioScience (AYTU) apparently took the President's musings to heart (the ones about the light, at least -- not the Clorox), announcing that it has signed an agreement with privately-held Sterling Medical Devices to help commercialize a light-based therapy developed by the Cedars-Sinai Health System to treat COVID-19.The device in question, dubbed "Healight," is described as a "novel endotracheal catheter," whereby a tube is inserted into a patient's endotracheal and nasopharyngeal (nose and throat) regions. Glowing and dousing a patient's innards with UV-light, it is hoped the device might prove to be "a safe and effective antiviral and antibacterial treatment" for defeating the SARS-CoV-19 coronavirus.As Aytu argues, Sterling, its chosen partner in this venture, "has a stellar reputation as a best-in-class medical device product firm with more than 21 years of experience." Out of "over 1,100 projects engineered ... none [have failed] to receive FDA regulatory approval upon submission," notes Aytu CEO Josh Disbrow. With Sterling's help, Aytu hopes it will be able to use Healight "to positively impact outcomes for critically ill patients infected with coronavirus and other infections."And so do investors -- who bid up Aytu's stock by more than 44% in Monday trading.Pie in the sky, you say? Perhaps. We do note Disbrow's clever language, potentially inflating Sterling's success rate with caveats such as "1,100 projects engineered" being approved only "upon submission." How many of those projects didn't pan out well enough to ever be submitted for FDA approval, one wonders?This isn't Aytu's first foray into COVID-19 work, however, nor its only chance of success. In a note recommending that investors "buy" the shares earlier this month, Ladenburg Thalmann analyst Jeffrey Cohen noted that the company is also distributing "COVID-19 IgM and IgG rapid tests" designed to detect the presence of COVID-19 antibodies in the capillary blood of infected patients. AytuBioScience has apparently already sold 100,000 such test kits into the market, and is working to obtain 500,000 more from the test's developer, Zhejiang Orient Gene Biotech Co., Ltd. in China. Based largely on its test kit business, Cohen postulates that Aytu stock could be worth $2.50 a share -- 38% more than what it currently sells for.And who knows? Even if the UV light thingamajig doesn't work out -- maybe the test kit venture will.Overall, Aytu has slipped under most analysts’ radar; the stock’s Moderate Buy consensus is based on just two recent ratings. With shares trading at $1.84, the $3.75 average price target suggests room for over 100% upside. (See Aytu stock analysis on TipRanks)To find good ideas for healthcare stocks trading at attractive valuations, visit TipRanks’ Best Stocks to Buy, a newly launched tool that unites all of TipRanks’ equity insights.
Researchers are working on a medical device that uses UV-A as a potential treatment for COVID-19 patients. But a study is in early stages.
Aytu BioScience, Inc.'s (NASDAQ:AYTU): Aytu BioScience, Inc., a specialty pharmaceutical company, focuses on developing...
ENGLEWOOD, CO / ACCESSWIRE / April 27, 2020 / Aytu BioScience, Inc. (AYTU) (the "Company"), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs announced today that it has signed an agreement with Sterling Medical Devices ("Sterling") to finalize the development of Healight, a novel endotracheal catheter, as a potential treatment for coronavirus. The company announced last week that it licensed exclusive worldwide rights to the Healight technology from Cedars-Sinai for all endotracheal and nasopharyngeal indications.
The "Global Antibiotics Partnering Terms and Agreements 2010 to 2020" report has been added to ResearchAndMarkets.com's offering.
Researchers are working on a medical device that uses UV-A as a potential treatment for COVID-19 patients. But a study is in early stages.
Aytu Bioscience, Inc. (AYTU) closed at $1.64 in the latest trading session, marking a +1.23% move from the prior day.
On Aytu BioScience's (AYTU) upcoming earnings call, investor focus will be on its distribution right to commercialize the COVID-19 IgG/IgM Rapid Test in North America.
The "Global Infectious Diseases Partnering Deals Collection 2014-2020: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering.
Aytu BioScience, Inc.'s (NASDAQ:AYTU): Aytu BioScience, Inc., a specialty pharmaceutical company, focuses on developing...
Aspen was an early COVID-19 hot spot in Colorado, with a cluster of cases in March linked to tourists visiting for its world-famous skiing. Tests were in short supply, making it difficult to know how the virus was spreading. So in April, when the Pitkin Count…
The U.S. Federal government is working closely with companies and researchers to find treatments and vaccines to overcome the global health crisis. The FDA has been cutting red tape and has launched new programs that relax certain time consuming regulations w…
ENGLEWOOD, CO / ACCESSWIRE / April 24, 2020 / Aytu BioScience, Inc. (AYTU) (the "Company"), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs, is pleased to report the results of the Company's 2020 Annual Meeting. Stockholders yesterday elected Joshua Disbrow, Steven Boyd, Gary Cantrell, Carl Dockery, John Donofrio, Jr, Michael Macaluso, and Ketan Mehta to the Company's Board of Directors for one-year terms. Stockholders approved an advisory vote on executive compensation, ratified the appointment of Plante & Moran, PLLC as the Company's independent auditor for 2020, and approved the Company's Board of Directors to authorize a reverse split of the Company's common stock.
Company Reports Revenue for the Three Months Ended March 31, 2020 of $8.2M, Up 243% Year-over-Year $62.5 Million in Cash and Cash Equivalents as of March 31, 2020 Management to Host Conference Call at ...
The "Global Cancer Diagnostics Partnering Terms and Agreements 2014-2020" report has been added to ResearchAndMarkets.com's offering.
NRPLUS MEMBER ARTICLE L ong periods of social isolation can lead to insanity. When I turned to Twitter one day last week and found that the trending items under “politics” included Lysol, DisinfectantInjection and the surely superfluous DontDrinkBleach, I beg…
The smid-cap biotech earnings deluge hit Wall Street in the week ended May 9, positively impacting the stocks in the sector. The iShares NASDAQ Biotechnology Index (NASDAQ: IBB) gained about 6% for the week.Large-cap pharma names AstraZeneca plc (NYSE: AZN) a…
Big Tech companies should make up their minds. Are they public fora, open to one and all, that faithfully carry an infinite spectrum of messages — much as AT&T phone lines transmit liberal, moderate, and conservative robocalls during election season? Or are t…
Is (AYTU) Outperforming Other Medical Stocks This Year?
On Aytu BioScience's (AYTU) upcoming earnings call, investor focus will be on its distribution right to commercialize the COVID-19 IgG/IgM Rapid Test in North America.
ENGLEWOOD, CO / ACCESSWIRE / April 23, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU) (the "Company"), a specialty pharmaceutical company focused on commercializing novel products that address significant ...
"A question that probably some of you are thinking of ... which I find to be very interesting. So, supposedly we hit the body with a tremendous, whether it’s ultraviolet or just very powerful light... inside the body ... Sounds interesting, right? ... It soun…
Cedars-Sinai is embroiled in a political battle over Trump's remarks on a potential virus treatment.
Cedars-Sinai is embroiled in a political battle over Trump's remarks on a potential virus treatment.
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of Aytu BioScience, Inc. (AYTU) on Behalf of Investors
Donald Trump was widely ridiculed for suggesting that injecting disinfectant into the lungs of coronavirus patients could wipe out the disease. Although the US President undoubtedly got the wrong end of the stick, it has emerged that one company really is hop…
(Bloomberg) -- When President Donald Trump suggested on Thursday that injecting disinfectant or ultraviolet light into the body could be a way to kill the coronavirus, his comments were widely criticized as harmful.But for one U.S. company, the president’s re…
ENGLEWOOD, CO / ACCESSWIRE / May 7, 2020 / Aytu BioScience, Inc. (NASDAQ:AYTU) (the "Company"), a specialty pharmaceutical company focused on commercializing novel products that address significant ...
Aytu Bioscience, Inc. (AYTU) delivered earnings and revenue surprises of 61.54% and 16.51%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Aytu BioScience, Inc. (AYTU) on Behalf of Investors
Is (AYTU) Outperforming Other Medical Stocks This Year?
Aytu Bioscience Inc (AYTU) closed the most recent trading day at $1.47, moving +1.38% from the previous trading session.
Journalism is a long-lost art, once used to inform people, reporting news in an unbiased manner, offering reasoned opinion in a balanced way. Now the singular goal of most American journalism is to make President Trump look bad, parsing his words or ...
The "Global Metabolic Partnering 2014-2020: Deal Trends, Players and Financials" report has been added to ResearchAndMarkets.com's offering.
The Law Offices of Frank R. Cruz announces an investigation on behalf of Aytu BioScience Inc. ("Aytu" or the Company") (NASDAQ: AYTU) investors concerning the Company and its officers’ possible violations of federal securities laws.
Aytu Bioscience, Inc. (AYTU) delivered earnings and revenue surprises of 61.54% and 16.51%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Aytu Bioscience Inc (AYTU) closed the most recent trading day at $1.47, moving +1.38% from the previous trading session.
Pomerantz LLP is investigating claims on behalf of investors of Aytu BioSciences, Inc. (“Aytu” or the “Company”) (NASDAQ: AYTU). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. The investigation concerns whether Aytu and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
ENGLEWOOD, CO / ACCESSWIRE / April 30, 2020 / Aytu BioScience, Inc. (AYTU) (the "Company"), a specialty pharmaceutical company focused on commercializing novel products that address significant patient needs announced today that it has received confirmation of export approval for product shipment by China's Ministry of Commerce for the Company's COVID-19 IgG/IgM Rapid Test. Aytu BioScience, Inc. is a commercial-stage specialty pharmaceutical company focused on commercializing novel products that address significant patient needs.
Aytu Bioscience, Inc. (AYTU) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.